| |
Int Clin Psychopharmacol, Vol. 22, No. 6. (November 2007), pp. 330-337.
|
| |
Drug Saf, Vol. 30, No. 7. (2007), pp. 555-567.
|
| |
Mov Disord, Vol. 22, No. 4. (15 March 2007), pp. 570-573.
|
| |
Biomedecine & Pharmacotherapy, Vol. 60, No. 7. (August 2006), pp. 318-322.
|
| |
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 6, No. 1. (February 2007), pp. 17-29.
|
| |
N Engl J Med, Vol. 356, No. 17. (26 April 2007), pp. 1711-1722.
by Gary S. Sachs, Andrew A. Nierenberg, Joseph R. Calabrese, et al.Lauren B. Marangell, Stephen R. Wisniewski, Laszlo Gyulai, Edward S. Friedman, Charles L. Bowden, Mark D. Fossey, Michael J. Ostacher, Terence A. Ketter, Jayendra Patel, Peter Hauser, Daniel Rapport, James M. Martinez, Michael H. Allen, David J. Miklowitz, Michael W. Otto, Ellen B. Dennehy, Michael E. Thase
|
| |
Drug Safety, Vol. 30, No. 2. (2007), pp. 171-184.
|
| |
CNS Drugs, Vol. 20, No. 3. (2006), pp. 187-198.
|
| |
Drug Saf, Vol. 29, No. 2. (2006), pp. 95-118.
|
| |
Am J Psychiatry, Vol. 164, No. 2. (1 February 2007), pp. 342-345.
|
| |
British Journal of Clinical Pharmacology, Vol. 61, No. 2. (February 2006), pp. 191-199.
|
| |
Neurology, Vol. 67, No. 11. (12 December 2006), pp. 1916-1925.
|
| |
CNS Spectr, Vol. 10, No. 3. (March 2005), pp. 224-232.
|
| |
Am J Psychiatry, Vol. 163, No. 7. (July 2006), pp. 1199-1201.
|
| |
Clin Neuropharmacol, Vol. 29, No. 5. (t 2006), pp. 265-268.
|
| |
J Psychopharmacol, Vol. 19, No. 3. (May 2005), pp. 287-291.
|
